AVIR — Atea Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $324.03m
- $104.56m
Brief: Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025
Brief: Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program
Brief: Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus
Brief: The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
Brief: Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff
Atea Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Atea Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview
Atea Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Bradley L. Radoff And Michael Torok Calls For Atea Pharmaceuticals To Appoint New, Lead Independent Director To Oversee Strategic Review Process
U.S. STOCKS ON THE MOVE-Stoke Therapeutics, Foot Locker, Marvell
U.S. STOCKS ON THE MOVE-Nano Nuclear, JetBlue, Cross Country
U.S. STOCKS ON THE MOVE-Eli Lilly, GM, Dollar Tree
Atea Pharma rises as combo drug meets main goal in mid-stage study
Atea Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Atea Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing
U.S. STOCKS ON THE MOVE-Uber, silver miners, Arm
U.S. STOCKS ON THE MOVE-Atea Pharmaceuticals, Adobe, Similarweb
Atea Pharma falls after COVID drug fails in late-stage study
Brief: Atea Pharmaceuticals Provides Update On Global Phase 3 Sunrise-3 Trial Evaluating Bemnifosbuvir For Treatment Of Covid-19